ストックスクリーナーアプリを入手
1.04
0.97%
0.01
アフターアワーズ：
1.03
-0.01
-0.96%
前日終値:
$1.03
開ける：
$1.03
24時間の取引高:
332.56K
Relative Volume:
0.60
時価総額：
$59.18M
収益：
$10.33M
当期純損益:
$-129.77M
株価収益率:
-1.0401
EPS:
-0.9999
ネットキャッシュフロー:
$-140.33M
1週間 パフォーマンス:
-2.80%
1か月 パフォーマンス:
-6.31%
6か月 パフォーマンス:
-41.57%
1年 パフォーマンス:
-28.03%
1日の値動き範囲:
$1.03
$1.06
1週間の範囲:
$1.00
$1.07
52週間の値動き範囲:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Compare TCRX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.04 | 58.61M | 10.33M | -129.77M | -140.33M | -0.9999 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | 開始されました | BTIG Research | Buy |
| 2024-05-13 | 開始されました | Needham | Buy |
| 2023-06-22 | 開始されました | Wedbush | Outperform |
Tscan Therapeutics Inc (TCRX) 最新ニュース
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Yahoo Finance UK
Earnings Risk: Will TScan Therapeutics Inc stock benefit from M A2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aug Catalysts: Will TScan Therapeutics Inc outperform its industry peersQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
How does TScan Therapeutics Inc score in quality rankings2026 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Risk Check: Will TScan Therapeutics Inc outperform its industry peersMarket Sentiment Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Geopolitics Watch: Is TScan Therapeutics Inc. stock risky to hold now2026 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TCRXTscan Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00 - Defense World
TCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
What are the risks of holding TScan Therapeutics Inc2025 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Stop Loss: What is the next catalyst for TScan Therapeutics Inc2025 Market WrapUp & Weekly Return Optimization Alerts - baoquankhu1.vn
HC Wainwright Issues Positive Outlook for TCRX Earnings - MarketBeat
FY2030 Earnings Estimate for TCRX Issued By HC Wainwright - MarketBeat
Tscan Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
TCRX: Pivotal trial for relapse-preventing T-cell therapy launches in Q2, targeting major market expansion - TradingView
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
TScan Therapeutics, Inc. (TCRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
TScan Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
The latest financial data from biotechnology company Tscan Therapeutics, Inc. shows that its current cash and cash equivalents are sufficient to support the company's daily operations and R&D investment through the second half of 2027. - Bitget
TScan Therapeutics 10-K: $10.3M Collaboration Revenue, $(129.8)M Net Loss - TradingView
TScan Therapeutics (NASDAQ: TCRX) advances TSC-101 and reshapes pipeline - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) details 2025 loss, growth and cash runway - Stock Titan
Earnings Breakdown: TScan Therapeutics Q4 - Benzinga
TScan Therapeutics Q4 net loss widens - TradingView
BRIEF-TScan Therapeutics Q4 Net Income USD -22.977 Million - TradingView
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Needham Reaffirms Their Buy Rating on TScan Therapeutics (TCRX) - The Globe and Mail
TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial - marketscreener.com
TScan Therapeutics Completes Enrollment in Cohort C of - GlobeNewswire
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 - ChartMill
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
TScan Therapeutics to Present at TD Cowen 46th Annual Health Care Conference on March 4, 2026 - Quiver Quantitative
TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
TScan to present cancer T cell therapy work at TD Cowen health conference - Stock Titan
Is TScan Therapeutics Inc. stock a good dividend stockWeekly Stock Report & Risk Controlled Daily Plans - mfd.ru
TScan Therapeutics (NASDAQ:TCRX) Trading Up 4.6%Here's What Happened - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Is TScan Therapeutics Inc. stock a value trap2025 Sector Review & Low Drawdown Trading Techniques - mfd.ru
What’s next for TScan Therapeutics Inc. stockQuarterly Market Review & Comprehensive Market Scan Insights - mfd.ru
What are TScan Therapeutics Inc.’s technical support levels2025 Momentum Check & Capital Protection Trade Alerts - mfd.ru
Net income of Tscan Therapeutics from 2020 to 2024 - Statista
Analysis Recap: Will TScan Therapeutics Inc outperform its industry peersJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug Highlights: How liquid is BlackRock ESG Capital Allocation Term Trust stock2025 Pullback Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Activity Recap: Will TScan Therapeutics Inc outperform its industry peersMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Tscan Therapeutics Inc (TCRX) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):